Doer Biologics begins patient dosing in phase 2 study of DR10624 to treat metabolic dysfunction-associated steatotic liver disease and MASH: Hangzhou, China Thursday, April 24, 20 ...

DelveInsight’s, “Metastatic Colorectal Cancer Pipeline Insight 2025” report provides comprehensive insights about 150+ ...

Incyte (Nasdaq: INCY) today announced that multiple abstracts featuring new data from its oncology portfolio will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, ...

A recent publication in Genes & Diseases has delivered a compelling synthesis of the latest insights into the cellular ...

89bio, Inc. is a clinical-stage biotech focused on liver and cardio-metabolic diseases, with its lead drug candidate ...

Pancreatic cancer is one of the most aggressive cancers and has one of the lowest survival rates-only 10% after five years.

A study demonstrates the role of the Galectin-1 protein in the nucleus of the cells surrounding the tumor -- fibroblasts -- contributing to their activation. Activated fibroblasts promote tumor growth ...

Now, with quick commerce beginning to emerge as the next, and potentially even bigger, opportunity in the country’s ecommerce market, Gupta is preparing Yulu to tap that growth. “The humongous ...

Premium and loyalty revenues increased approximately 7%, bolstered by a 13% growth in remuneration from American Express, totaling $2 billion. Free cash flow reached $1.3 billion, with $1.4 ...

and fibroblast growth factor receptor 1 (FGFR1), are validated drug targets for therapeutic intervention, others remain challenging and are not yet amenable to modulation by anticancer agents.

On a sequential basis, total deposits rose by 10.1 per cent. The lender’s total advances grew by 17.8 per cent year-on-year to Rs 2.4 trillion, while on a quarterly basis, advances were up by 5 per ...